• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

甲胎蛋白和异常凝血酶原在活体肝移植后肝癌中的长期预后价值:一项单中心回顾性研究

Long-Term Prognostic Value of AFP and PIVKA-II in HCC After Living Donor Liver Transplantation: A Single-Center Retrospective Study.

作者信息

Gongor Saran Ochir, Choi YoungRok, Kim Gayoung, Kim Min Kyoung, Park Sang Hyuk, Kim Jiyoung, Kim Jae-Yoon, Hong Su Young, Lee Jeong-Moo, Hong Suk Kyun, Lee Kwang-Woong

机构信息

Department of Surgery, Seoul National University College of Medicine, Seoul, Republic of Korea.

Department of Surgery, Seoul National University Hospital, Seoul, Republic of Korea.

出版信息

Transpl Int. 2025 Jun 27;38:14748. doi: 10.3389/ti.2025.14748. eCollection 2025.

DOI:10.3389/ti.2025.14748
PMID:40656560
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12245734/
Abstract

Despite the development of numerous prognostic models for hepatocellular carcinoma (HCC) recurrence and mortality after liver transplantation, tumor biomarkers such as alpha-fetoprotein (AFP) and protein induced by vitamin K absence-II (PIVKA-II) remain widely used in clinical practice. This study evaluated the performance of AFP and PIVKA-II compared with six prognostic models (RETREAT, SNAPP, MoRAL, R3-AFP, METROTICKET 2.0, and SALT) in a retrospective cohort of 707 adults who underwent living donor liver transplantation (LDLT) for HCC between 2003 and 2018. Patients were stratified into Milan and Beyond Milan groups. Time-dependent receiver operating characteristic curve analysis was conducted using integrated area under the curve (iAUC) and concordance index (C-index) to assess recurrence and mortality. AFP and PIVKA-II (continuous) achieved iAUCs of 0.68-0.75 for recurrence and C-indices of 0.66-0.77 for mortality. Their combination reached iAUCs up to 0.78 and C-indices up to 0.80. Threshold models (AFP ≥200, PIVKA-II ≥400) showed modest predictive performance. Among multivariable models, R3-AFP demonstrated the most consistent performance (iAUC 0.76-0.81; C-index 0.78-0.82). SNAPP, MoRAL, and SALT also performed well. AFP and PIVKA-II may offer practical utility in resource-limited settings. However, multivariable models remain the preferred approach where comprehensive diagnostics are available.

摘要

尽管已经开发出许多用于预测肝细胞癌(HCC)肝移植后复发和死亡率的模型,但甲胎蛋白(AFP)和维生素K缺乏诱导蛋白-II(PIVKA-II)等肿瘤生物标志物在临床实践中仍被广泛使用。本研究在一项回顾性队列研究中,评估了AFP和PIVKA-II与六种预后模型(RETREAT、SNAPP、MoRAL、R3-AFP、METROTICKET 2.0和SALT)相比的性能,该队列研究纳入了2003年至2018年间因HCC接受活体肝移植(LDLT)的707名成年人。患者被分为米兰标准组和超出米兰标准组。使用曲线下综合面积(iAUC)和一致性指数(C指数)进行时间依赖性受试者工作特征曲线分析,以评估复发和死亡率。AFP和PIVKA-II(连续变量)复发的iAUC为0.68-0.75,死亡率的C指数为0.66-0.77。它们的联合使用iAUC高达0.78,C指数高达0.80。阈值模型(AFP≥200,PIVKA-II≥400)显示出适度的预测性能。在多变量模型中,R3-AFP表现出最一致的性能(iAUC 0.76-0.81;C指数0.78-0.82)。SNAPP、MoRAL和SALT也表现良好。AFP和PIVKA-II在资源有限的环境中可能具有实际用途。然而,在可进行全面诊断的情况下,多变量模型仍然是首选方法。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/51bd/12245734/93a72ca81399/ti-38-14748-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/51bd/12245734/bbdd37ed7861/ti-38-14748-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/51bd/12245734/2c00cce34f11/ti-38-14748-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/51bd/12245734/cb07f6c44dc2/ti-38-14748-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/51bd/12245734/21ad7eb88eac/ti-38-14748-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/51bd/12245734/93a72ca81399/ti-38-14748-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/51bd/12245734/bbdd37ed7861/ti-38-14748-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/51bd/12245734/2c00cce34f11/ti-38-14748-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/51bd/12245734/cb07f6c44dc2/ti-38-14748-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/51bd/12245734/21ad7eb88eac/ti-38-14748-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/51bd/12245734/93a72ca81399/ti-38-14748-g005.jpg

相似文献

1
Long-Term Prognostic Value of AFP and PIVKA-II in HCC After Living Donor Liver Transplantation: A Single-Center Retrospective Study.甲胎蛋白和异常凝血酶原在活体肝移植后肝癌中的长期预后价值:一项单中心回顾性研究
Transpl Int. 2025 Jun 27;38:14748. doi: 10.3389/ti.2025.14748. eCollection 2025.
2
Prothrombin-induced by vitamin K absence II as a prognostic factor in living donor liver transplantation for hepatocellular carcinoma.维生素K缺乏诱导的凝血酶原II作为肝细胞癌活体肝移植预后因素的研究
Sci Rep. 2025 Jul 1;15(1):21900. doi: 10.1038/s41598-025-08103-1.
3
Cluster analysis of hepatocellular carcinoma prognosis using preoperative alpha-fetoprotein and des-gamma-carboxy prothrombin levels: a multi-institutional study.利用术前甲胎蛋白和异常凝血酶原水平对肝细胞癌预后进行聚类分析:一项多机构研究
J Gastrointest Surg. 2025 Apr;29(4):101980. doi: 10.1016/j.gassur.2025.101980. Epub 2025 Jan 28.
4
Usefulness of PIVKA-II After Living-donor Liver Transplantation for Hepatocellular Carcinoma.活体肝移植治疗肝细胞癌后异常凝血酶原-II的应用价值
Transplant Proc. 2017 Jun;49(5):1109-1113. doi: 10.1016/j.transproceed.2017.03.017.
5
Diagnostic and Prognostic Value of Combined Detection of Serum Protein Induced by Vitamin K Absence or Antagonist-II, Alpha-Fetoprotein, and Spliced Hepatitis B Virus in Hepatitis B Virus-Induced Hepatocellular Carcinoma.维生素K缺乏或拮抗剂-II诱导的血清蛋白、甲胎蛋白和剪接型乙型肝炎病毒联合检测在乙型肝炎病毒诱导的肝细胞癌中的诊断和预后价值
Cancer Biother Radiopharm. 2025 Jul 2. doi: 10.1089/cbr.2025.0085.
6
Performance of the GALAD Model in an Asian Cohort Undergoing Hepatocellular Carcinoma Surveillance: A Prospective Cohort Study.GALAD模型在接受肝细胞癌监测的亚洲队列中的表现:一项前瞻性队列研究。
J Gastroenterol Hepatol. 2025 Jul;40(7):1818-1824. doi: 10.1111/jgh.16997. Epub 2025 May 10.
7
Diagnostic and prognostic performance of serum GPC3 and PIVKA-II in AFP-negative hepatocellular carcinoma and establishment of nomogram prediction models.血清GPC3和异常凝血酶原在甲胎蛋白阴性肝细胞癌中的诊断和预后性能及列线图预测模型的建立
BMC Cancer. 2025 Apr 17;25(1):721. doi: 10.1186/s12885-025-14025-y.
8
Patient Selection by Tumor Markers in Liver Transplantation for Advanced Hepatocellular Carcinoma.肝移植治疗晚期肝细胞癌中肿瘤标志物对患者的选择。
Liver Transpl. 2018 Sep;24(9):1243-1251. doi: 10.1002/lt.25056.
9
Tumor marker levels before and after curative treatment of hepatocellular carcinoma as predictors of patient survival.肝癌根治性治疗前后肿瘤标志物水平与患者生存的预测价值。
Dig Dis Sci. 2011 Oct;56(10):3086-100. doi: 10.1007/s10620-011-1796-6. Epub 2011 Jun 25.
10
Prognostic significance of postoperative serological incomplete conversion of AFP and PIVKA-II after hepatic resection for hepatocellular carcinoma: a multicenter analysis of 1755 patients.肝细胞癌肝切除术后甲胎蛋白(AFP)和异常凝血酶原(PIVKA-II)血清学不完全转化的预后意义:1755例患者的多中心分析
Oncologist. 2024 Dec 6;29(12):e1723-e1733. doi: 10.1093/oncolo/oyae139.

本文引用的文献

1
Enhancing the prognostic accuracy of the RETREAT score with AFP-L3 and DCP tumor markers.利用甲胎蛋白异质体L3(AFP-L3)和异常凝血酶原(DCP)肿瘤标志物提高RETREAT评分的预后准确性。
Liver Transpl. 2025 Jun 1;31(6):727-736. doi: 10.1097/LVT.0000000000000551. Epub 2024 Dec 12.
2
Validation of the R3-AFP model for risk prediction of HCC recurrence after liver transplantation in the SiLVER randomized clinical trial.在SILVER随机临床试验中验证R3-AFP模型对肝移植后肝癌复发的风险预测作用。
Liver Transpl. 2025 Jan 1;31(1):45-57. doi: 10.1097/LVT.0000000000000487. Epub 2024 Sep 20.
3
Recurrence risk prediction models for hepatocellular carcinoma after liver transplantation.
肝移植后肝细胞癌的复发风险预测模型
J Gastroenterol Hepatol. 2024 Nov;39(11):2272-2280. doi: 10.1111/jgh.16693. Epub 2024 Aug 7.
4
Research progress of protein induced by vitamin K absence or antagonist II in liver transplantation for hepatocellular carcinoma.维生素K缺乏或拮抗剂II诱导蛋白在肝细胞癌肝移植中的研究进展
Heliyon. 2024 May 3;10(9):e30622. doi: 10.1016/j.heliyon.2024.e30622. eCollection 2024 May 15.
5
The Role of PIVKA-II as a Predictor of Early Hepatocellular Carcinoma Recurrence-Free Survival after Liver Transplantation in a Low Alpha-Fetoprotein Population.在低甲胎蛋白人群中,异常凝血酶原-II作为肝移植后早期肝细胞癌无复发生存预测指标的作用
Cancers (Basel). 2023 Dec 19;16(1):4. doi: 10.3390/cancers16010004.
6
Liver Transplantation.肝移植
N Engl J Med. 2023 Nov 16;389(20):1888-1900. doi: 10.1056/NEJMra2200923.
7
Role of protein induced by vitamin-K absence-II in transplanted patients with HCC not producing alpha-fetoprotein.维生素 K 拮抗剂诱导蛋白在不产生甲胎蛋白的 HCC 移植患者中的作用。
Liver Transpl. 2024 May 1;30(5):472-483. doi: 10.1097/LVT.0000000000000259. Epub 2023 Sep 19.
8
Long-term outcomes (beyond 5 years) of liver transplant recipients-A transatlantic multicenter study.肝移植受者的长期预后(5 年以上)——一项跨大西洋多中心研究。
Liver Transpl. 2024 Feb 1;30(2):170-181. doi: 10.1097/LVT.0000000000000244. Epub 2023 Aug 18.
9
Liver transplantation immunology: Immunosuppression, rejection, and immunomodulation.肝移植免疫:免疫抑制、排斥和免疫调节。
J Hepatol. 2023 Jun;78(6):1199-1215. doi: 10.1016/j.jhep.2023.01.030.
10
Utility of combining PIVKA-II and AFP in the surveillance and monitoring of hepatocellular carcinoma in the Asia-Pacific region.联合检测 PIVKA-II 和 AFP 在亚太地区肝细胞癌监测和随访中的应用。
Clin Mol Hepatol. 2023 Apr;29(2):277-292. doi: 10.3350/cmh.2022.0212. Epub 2023 Jan 30.